Does a high AA:EPA ratio indicate dominance of arachidonic-acid-derived eicosanoid signaling?

The arachidonic acid (AA) to eicosapentaenoic acid (EPA) ratio is a scientifically validated biomarker that reflects the metabolic balance of lipid signaling molecules. In a 73-year-old female, maintaining an optimal ratio is particularly relevant for cardiovascular health and the management of systemic inflammation.

Mechanistic explanations

• Substrate Competition: AA and EPA compete for the same enzymatic pathways, primarily cyclooxygenase (COX-1 and COX-2) and lipoxygenase (5-LOX). Because these enzymes have shared binding sites, the relative concentration of each fatty acid dictates which downstream mediators are produced.
• Thromboxane Shift: In platelets, high AA levels favor the production of Thromboxane A2 (TXA2), a potent driver of platelet aggregation and vessel narrowing. Increasing EPA levels leads to the production of Thromboxane A3 (TXA3). While chemically similar, TXA3 is a significantly weaker agonist at the thromboxane (TP) receptor, effectively reducing the overall pro-thrombotic signal.
• Leukotriene and Resolvin Production: AA metabolism via the 5-LOX pathway produces 4-series leukotrienes (like LTB4), which are highly inflammatory. EPA shifts this toward 5-series leukotrienes and, crucially, serves as the precursor for E-series resolvins. These specialized pro-resolving mediators (SPMs) do not just "lower" inflammation but actively signal for its resolution.
• Membrane Displacement: EPA competitively displaces AA from the sn-2 position of membrane phospholipids. This reduces the pool of AA available for release by phospholipase A2, thereby limiting the starting material for pro-inflammatory signaling at its source.

Clinical evidence

• Anti-thrombotic Effects: Clinical data consistently show that increasing the EPA:AA ratio through supplementation dose-dependently inhibits platelet aggregation. Studies demonstrate that even in the presence of other antiplatelet therapies, high EPA levels further reduce platelet reactivity by blunting TP receptor-mediated intracellular calcium signaling.
• Inflammatory Profiles: In human clinical trials, a higher EPA:AA ratio is associated with lower circulating levels of C-reactive protein (CRP) and other inflammatory markers. The shift from 2-series to 3-series prostaglandins is a hallmark of this nutritional intervention.

Practical considerations

• Enzymatic Preference: While EPA is a competitive inhibitor, COX-1/2 enzymes generally have a higher catalytic efficiency for AA. This means that significant increases in EPA intake (often via high-dose fish oil) are typically required to effectively "outcompete" AA and shift the signaling dominance toward a less inflammatory state.

Bottom line

A high AA:EPA ratio indicates a physiological state primed for pro-inflammatory and pro-thrombotic signaling. EPA effectively shifts this balance by competing for metabolic enzymes, resulting in the production of biologically weaker "3-series" mediators and potent "pro-resolving" molecules that mitigate vascular and inflammatory risks.